Axon Enterprise - AXON Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $365.38
  • Forecasted Upside: -16.00%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$434.98
▲ +6.22 (1.45%)

This chart shows the closing price for AXON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Axon Enterprise Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXON

Analyst Price Target is $365.38
▼ -16.00% Downside Potential
This price target is based on 14 analysts offering 12 month price targets for Axon Enterprise in the last 3 months. The average price target is $365.38, with a high forecast of $430.00 and a low forecast of $233.00. The average price target represents a -16.00% upside from the last price of $434.98.

This chart shows the closing price for AXON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in Axon Enterprise. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/14/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/13/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/11/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/11/2024

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/12/2024JMP SecuritiesBoost TargetOutperform$375.00 ➝ $430.00
9/10/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$360.00 ➝ $400.00
9/9/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$375.00 ➝ $375.00
8/8/2024Northland SecuritiesBoost TargetOutperform ➝ Outperform$330.00 ➝ $365.00
8/7/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$375.00 ➝ $375.00
8/7/2024Craig HallumBoost TargetBuy ➝ Buy$370.00 ➝ $376.00
8/7/2024BarclaysBoost TargetOverweight ➝ Overweight$381.00 ➝ $387.00
8/7/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$355.00 ➝ $360.00
8/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$400.00 ➝ $400.00
7/17/2024Bank of AmericaInitiated CoverageBuy$380.00
7/17/2024Jefferies Financial GroupInitiated CoverageBuy$385.00
5/8/2024BarclaysBoost TargetOverweight ➝ Overweight$308.00 ➝ $381.00
5/7/2024Craig HallumBoost TargetBuy ➝ Buy$325.00 ➝ $370.00
5/7/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$375.00
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$400.00
5/1/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$320.00 ➝ $375.00
4/26/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$285.00 ➝ $310.00
4/24/2024William BlairReiterated RatingOutperform
4/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$400.00
4/11/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$330.00 ➝ $365.00
4/10/2024Needham & Company LLCBoost TargetBuy ➝ Buy$315.00 ➝ $400.00
3/13/2024ArgusInitiated CoverageBuy$380.00
2/29/2024BarclaysBoost TargetOverweight ➝ Overweight$296.00 ➝ $308.00
2/28/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$250.00 ➝ $285.00
2/28/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$297.00 ➝ $339.00
2/28/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$285.00 ➝ $330.00
2/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$240.00 ➝ $315.00
2/22/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$260.00 ➝ $300.00
2/6/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$250.00 ➝ $285.00
2/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$240.00
1/2/2024BarclaysBoost TargetOverweight ➝ Overweight$247.00 ➝ $296.00
11/8/2023Raymond JamesBoost TargetOutperform ➝ Outperform$223.00 ➝ $233.00
9/29/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$235.00
8/22/2023Morgan StanleyInitiated CoverageEqual Weight$230.00
8/11/2023Northland SecuritiesBoost TargetOutperform ➝ Outperform$227.00 ➝ $235.00
8/9/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$240.00
8/9/2023BarclaysLower TargetOverweight ➝ Overweight$256.00 ➝ $239.00
5/11/2023Robert W. BairdBoost Target$237.00 ➝ $240.00
5/11/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$236.00
5/10/2023Credit Suisse GroupBoost Target$300.00 ➝ $309.00
5/10/2023BarclaysBoost Target$222.00 ➝ $256.00
4/14/2023JMP SecuritiesReiterated RatingMarket Outperform$235.00
4/13/2023Needham & Company LLCReiterated RatingBuy$240.00
4/11/2023Credit Suisse GroupBoost TargetOutperform$237.00 ➝ $300.00
3/7/2023The Goldman Sachs GroupInitiated CoverageBuy$263.00
3/2/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$224.00
3/2/2023BarclaysBoost TargetOverweight$177.00 ➝ $222.00
3/1/2023Needham & Company LLCReiterated RatingBuy$240.00
3/1/2023Craig HallumBoost Target$215.00 ➝ $242.00
3/1/2023Robert W. BairdBoost TargetOutperform$200.00 ➝ $237.00
3/1/2023Credit Suisse GroupBoost TargetOutperform$200.00 ➝ $237.00
2/17/2023Raymond JamesDowngradeStrong-Buy ➝ Outperform$223.00
2/1/2023JMP SecuritiesBoost TargetMarket Outperform$195.00 ➝ $235.00
1/25/2023Needham & Company LLCBoost Target$200.00 ➝ $240.00
1/10/2023Credit Suisse GroupBoost TargetOutperform$152.00 ➝ $200.00
12/15/2022Robert W. BairdBoost Target$170.00 ➝ $200.00
12/13/2022Morgan StanleyBoost TargetEqual Weight$130.00 ➝ $155.00
11/15/2022Robert W. BairdBoost Target$170.00
11/9/2022Northland SecuritiesBoost Target$140.00 ➝ $160.00
11/9/2022Needham & Company LLCBoost TargetBuy$130.00 ➝ $200.00
11/9/2022Morgan StanleyBoost TargetEqual Weight$120.00 ➝ $130.00
11/9/2022Credit Suisse GroupBoost TargetOutperform$142.00 ➝ $152.00
9/15/2022BarclaysInitiated CoverageOverweight$147.00
8/18/2022Robert W. BairdBoost TargetOutperform$130.00 ➝ $150.00
8/10/2022Credit Suisse GroupBoost TargetOutperform$134.00 ➝ $142.00
7/14/2022Credit Suisse GroupLower Target$169.00 ➝ $134.00
6/1/2022JMP SecuritiesReiterated RatingBuy$195.00
5/23/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$120.00
5/12/2022Northland SecuritiesLower Target$180.00 ➝ $130.00
5/11/2022Robert W. BairdLower Target$145.00 ➝ $125.00
5/9/2022Credit Suisse GroupInitiated CoverageOutperform$169.00
2/28/2022Northland SecuritiesLower Target$220.00 ➝ $180.00
2/25/2022Robert W. BairdReiterated RatingBuy$175.00
2/25/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$222.00 ➝ $192.00
2/25/2022Needham & Company LLCLower TargetBuy$250.00 ➝ $170.00
12/15/2021Morgan StanleyLower TargetOverweight$200.00 ➝ $180.00
12/14/2021JMP SecuritiesInitiated CoverageOutperform$195.00
11/16/2021William BlairReiterated RatingOutperform
11/16/2021Craig HallumUpgradeHold ➝ Buy$232.00
8/6/2021Raymond JamesBoost TargetStrong-Buy$200.00 ➝ $223.00
8/6/2021Needham & Company LLCBoost TargetBuy$190.00 ➝ $250.00
8/6/2021Robert W. BairdBoost TargetPositive ➝ Outperform$195.00 ➝ $220.00
6/30/2021Raymond JamesBoost TargetStrong-Buy$150.00 ➝ $200.00
5/19/2021Raymond JamesUpgradeMarket Perform ➝ Strong-Buy$150.00
2/26/2021Northland SecuritiesInitiated CoverageBuy$170.00
2/26/2021Needham & Company LLCReiterated RatingBuy
2/26/2021Robert W. BairdBoost TargetOutperform$135.00 ➝ $200.00
2/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$129.00 ➝ $179.00
2/1/2021Morgan StanleyInitiated CoverageOverweight$185.00
10/23/2019JMP SecuritiesReiterated RatingOutperform$28.00 ➝ $32.00
(Data available from 10/11/2019 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 33 very positive mentions
  • 34 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
3/15/2024
  • 19 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/14/2024
  • 34 very positive mentions
  • 25 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
5/14/2024
  • 32 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2024
  • 17 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2024
  • 36 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/12/2024
  • 35 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/11/2024
  • 40 very positive mentions
  • 35 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/11/2024

Current Sentiment

  • 40 very positive mentions
  • 35 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Axon Enterprise logo
Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include axon officer safety plan; taser 10, taser7, taser X26P, taser X2, taser 7 CQ, and civilian series; cameras, such as axon body, axon flex, axon fleet, axon air, axon signal sidearm, axon signal vehicle, axon interview, and axon interview portable kit; software, including axon records, evidence, standards, commander, performance, auto-transcribe, justice, investigate, respond, and justice, my90, and redaction assistant; mobile applications, and training services, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. The company sells its products through its direct sales, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand bility to aggregate live video, data, and sensor feeds. It serves law enforcement, federal, correction, fire, EMS, campus, justice healthcare, retail, private security, and personal safety industries. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.
Read More

Today's Range

Now: $434.98
Low: $428.77
High: $436.40

50 Day Range

MA: $375.57
Low: $286.16
High: $432.14

52 Week Range

Now: $434.98
Low: $199.29
High: $436.55

Volume

334,478 shs

Average Volume

525,122 shs

Market Capitalization

$32.87 billion

P/E Ratio

114.77

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Axon Enterprise?

The following equities research analysts have issued reports on Axon Enterprise in the last twelve months: Argus, Bank of America Co., Barclays PLC, Craig Hallum, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Northland Securities, Raymond James, Robert W. Baird, StockNews.com, The Goldman Sachs Group, Inc., TheStreet, and William Blair.
View the latest analyst ratings for AXON.

What is the current price target for Axon Enterprise?

13 Wall Street analysts have set twelve-month price targets for Axon Enterprise in the last year. Their average twelve-month price target is $365.38, suggesting a possible downside of 15.5%. JMP Securities has the highest price target set, predicting AXON will reach $430.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $233.00 for Axon Enterprise in the next year.
View the latest price targets for AXON.

What is the current consensus analyst rating for Axon Enterprise?

Axon Enterprise currently has 1 hold rating and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AXON.

What other companies compete with Axon Enterprise?

Other companies that are similar to Axon Enterprise include Fortinet, Commvault Systems, Qualys, C3.ai and Progress Software. Learn More about companies similar to Axon Enterprise.

How do I contact Axon Enterprise's investor relations team?

Axon Enterprise's physical mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company's listed phone number is (480) 991-0797 and its investor relations email address is [email protected]. The official website for Axon Enterprise is www.axovant.com. Learn More about contacing Axon Enterprise investor relations.